IDH3A and glioma: Multiple studies have demonstrated that glioma patients with the molecular subtype of isocitrate dehydrogenase mutation (IDH mut) combined with O6-methylguanine-DNA methyltransferase promoter methylation (MGMT meth) have good overall survival and/or progression-free survival and can benefit from temozolomide (TMZ) chemotherapy.